Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
As well as funding the late-stage PQ Grass trial, the cash will also be used to part-fund the phase II study of Acarovac, the company’s dust mite allergy treatment
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
The injunction grant gives Indivior some much-needed breathing space, but it could all be in vain if US authorities eventually decide that Dr Reddy’s drug doesn’t infringe on any patents
Not only does it stop Dr Reddy’s from eating into Suboxone’s sales in the near-term, the temporary injunction grant bodes well for the wider patent case and might make it easier to strike deals with other rivals
“Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence”
The allergy vaccines maker expects to report a 6.6% rise in revenues for the year ended June 30
Quark has dosed the first patient in a phase III trial of its QPI-1002 drug which uses Silence’s chemical modification technology
The loss of four key customer contracts meant revenues slipped year-on-year, but CEO Jamal Rushdy thinks the changes it made in the wake of those issues leave the company in a better position
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now